Biotech Values

[DewDiligence]

…based on the cited ADXS anal-cancer drug efficacy, the respected Radiation Therapy Oncology Group (RTOG) has agreed to run a pivotal Phase 2/3 anal cancer trial in collaboration with Advaxis.

As you probably know, RTOG needs to get funding from the NCI to conduct this trial.

Of course, it’s possible I’m being naïve :- )

In all seriousness, RTOG’s involvement is another bullish pointer. Although we can’t yet say that ADVS’ cancer vaccines work, there are several encouraging signs.